Patients treated with Encelto who had smaller baseline ellipsoid zone area loss had better treatment response, according to a ...

An extension of the PHOTON trial shows that aflibercept 8 mg maintains long-term visual and anatomical improvements in ...

Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first ...

Advances in neovascular macular degeneration, presented at ASRS 2025, include efficacy of aflibercept 8 mg as well as ...

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME ...

Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -- CLS-AX ...

In this video, Yasha S. Modi, MD, discusses end-of-study results for EYP-1901 from EyePoint Pharmaceuticals, a bioerodible, sustained-release intravitreal insert to deliver vorolanib for diabetic ...

When we think of the age-old adage about getting old, "What new ache or pain will each new day bring?" we often imagine ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

A Utah woman in her 60s had glaucoma and hoped to protect her eye health through better nutrition. So she took a daily 20-mg ...

Macular degeneration is a common eye condition that affects millions of people worldwide. It is caused by the deterioration of the macula, the part of the eye responsible for central vision.